Arcellx, Inc. ACLX
We take great care to ensure that the data presented and summarized in this overview for Arcellx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACLX
View all-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$287 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$246 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$231 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$228 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$219 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.79MShares$183 Million3.44% of portfolio
-
Sr One Capital Management, LP2.35MShares$154 Million66.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.12MShares$139 Million0.02% of portfolio
-
State Street Corp Boston, MA1.78MShares$117 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.56MShares$102 Million0.06% of portfolio
Latest Institutional Activity in ACLX
Top Purchases
Top Sells
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at ACLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2025
|
Rami Elghandour |
BUY
Grant, award, or other acquisition
|
Direct |
1,015,671
+33.97%
|
-
|
|
Feb 26
2025
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
38,300
-7.27%
|
$2,336,300
$61.93 P/Share
|
|
Feb 25
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$94,500
$63.16 P/Share
|
|
Feb 25
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Feb 24
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,155
-7.54%
|
$649,920
$64.09 P/Share
|
|
Feb 07
2025
|
Rami Elghandour |
BUY
Exercise of conversion of derivative security
|
Direct |
140,422
+27.25%
|
-
|
|
Feb 07
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,112
+32.13%
|
-
|
|
Feb 04
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$96,000
$64.57 P/Share
|
|
Feb 04
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Jan 14
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-70.16%
|
$99,000
$66.3 P/Share
|
|
Jan 14
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Jan 08
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,997
-29.44%
|
$291,781
$73.69 P/Share
|
|
Jan 08
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,553
-12.41%
|
$259,369
$73.69 P/Share
|
|
Jan 08
2025
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
13,837
-10.55%
|
$1,010,101
$73.69 P/Share
|
|
Jan 07
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,012
-12.94%
|
$1,050,900
$75.78 P/Share
|
|
Jan 07
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,230
-12.87%
|
$317,250
$75.53 P/Share
|
|
Jan 07
2025
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
16,474
-11.16%
|
$1,235,550
$75.53 P/Share
|
|
Jan 06
2025
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
13,776
-8.45%
|
$1,060,752
$77.17 P/Share
|
|
Jan 06
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,122
-8.62%
|
$471,394
$77.17 P/Share
|
|
Jan 06
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,102
-15.31%
|
$392,854
$77.17 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 803K shares |
|---|---|
| Grant, award, or other acquisition | 1.02M shares |
| Open market or private sale | 1.05M shares |
|---|